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Many tumor cells are resistant to tumor necrosis factor alpha (TNFa)-induced apoptosis. Adenovirus early region 1A (AdE1A) sensitizes
the otherwise resistant cells to TNFa. AdE1A also stabilizes the p53 protein. The present study demonstrates a correlation between AdE1A-
induced sensitization and stabilization of p53 in TNFa-induced apoptosis since the N-terminal and CR2 regions, the binding sites for CBP/
p300, Rb and 26S proteasome regulatory components, are required for both these actions of AdE1A. TNFa does not induce apoptosis and
AdE1A fails to sensitize TNFa cytotoxicity in p53-negative cells. However, introduction of exogenous p53 overcomes the cellular resistance
to TNFa toxicity and enhances AdE1A sensitization, demonstrating that AdE1A sensitizes TNFa-induced apoptosis by its stabilization of
p53. A proteasome inhibitor, lactacystin, enhances TNFa cytotoxicity in p53-positive and -negative cells, suggesting that accumulation of
cellular proteins other than p53 might also regulate the cellular response to TNFa signaling.
D 2005 Elsevier Inc. All rights reserved.Keywords: Adenovirus; AdE1A; TNFa; p53; Apoptosis; 26S proteasome; CBP/p300; RbIntroduction
Adenovirus early region 1A (AdE1A) is the first protein to
be expressed following viral infection and can generate
diverse responses in host cells (Gallimore and Turnell, 2001;
Frisch and Mymryk, 2002). It initiates cell cycle progression,
driving quiescent cells into S phase, inhibits differentiation,
and can induce apoptosis or cell immortalization. AdE1A
produces these effects in the target cell by binding to a large
number of cellular proteins (Gallimore and Turnell, 2001;
Endter and Dobner, 2004). Twomajor products, referred to as
12S and 13S, are expressed and four highly conserved
regions (CR) identified in AdE1A from different viral
serotypes (Kimelman et al., 1985; Avvakumov et al., 2002,
2004). In Ad2/5, CR1 extends from residues 41 to 80 and0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.020
* Corresponding author. Fax: +44 121 4144486.
E-mail address: x.zhang.2@bham.ac.uk (X. Zhang).CR2 from 121 to 139, while CR3 is the region unique to the
larger 13S AdE1A and CR4 encompasses the C terminal
region. These conserved regions can serve as binding sites for
multiple cellular proteins. For example, the retinoblastoma
(Rb) family of tumor suppressor proteins binds to CR1 and
CR2 (Whyte et al., 1988; Jelsma et al., 1989). CR2 is also
required for AdE1A’s interaction with the S2 non-ATPase
regulatory subunit of the 26S proteasome (Zhang et al.,
2004). Components of the general and specific transcriptional
machinery (e.g., TBP and ATF2) bind to the 13S-specific
CR3 domain (Geisberg et al., 1994; Liu and Green, 1994),
and the C terminus of AdE1A (CR4) targets C-terminal
binding protein (CtBP) (Boyd et al., 1993; Chinnadurai,
2002, 2004). However, many cellular regulatory proteins
interact through the less highly conserved N-terminal region.
AdE1A can repress transcription of target genes by binding to
CREB-binding protein (CBP) and its homologue p300
through the N-terminal region and the C-terminal half of
CR1 (Eckner et al., 1994; Brockmann and Esche, 2003). In05) 285 – 295
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and the S4 and S8 ATPase regulatory components of the 26S
proteasome (Turnell et al., 2000; Zhang et al., 2004) have
been shown to bind close to the N-terminus. In vivo, it
appears that both the N-terminal region and CR2 are involved
in AdE1A interaction with the 26S proteasome (Zhang et al.,
2004).
AdE1A stabilizes the tumor suppressor protein p53 by
increasing its half-life (Braithwaite et al., 1990; Lowe and
Ruley, 1993; Querido et al., 1997). Accumulation of p53
induced by AdE1A can cause apoptosis under different
conditions (Debbas and White, 1993; Querido et al., 1997).
Additionally, AdE1A can trigger apoptosis through p53-
independent pathways (Chiou and White, 1997; Putzer et al.,
2000). So far, at least three mechanisms explaining AdE1A-
induced stabilization of p53 have been proposed. Firstly, p53
protein is stabilized due to AdE1A binding to CBP/p300
which regulates p53 degradation (Querido et al., 1997;
Somasundaram and El-Deiry, 1997; Grossman, 2001). CBP/
p300 promotes p53 degradation that is mediated by the
ubiquitin ligase Mdm2 (Thomas and White, 1998; Kawai et
al., 2001). It has been shown that CBP itself possesses an
intrinsic ubiquitin ligase activity, directly inducing poly-
ubiquitination of p53 (Grossman et al., 2003). Secondly, Rb
might play a role in the regulation of p53 stability in human
cells (Querido et al., 1997). Inactivation of Rb by AdE1A
induces accumulation of p19ARF that in turn induces p53
accumulation (de Stanchina et al., 1998; Samuelson et al.,
2005). Thirdly, p53 stabilization can be induced by AdE1A’s
specific interaction with, and inhibition of, the 26S
proteasome through the N-terminal and CR2 regions (Grand
et al., 1999; Turnell et al., 2000; Zhang et al., 2004). Notably,
AdE1A mutants lacking capacity to interact with the 26S
proteasome fail to stabilize p53.
Tumor necrosis factor-alpha (TNFa) is a multi-functional
cytokine that plays a critical role in controlling apoptosis in
many malignant cell types (Yagita et al., 2004; Gupta and
Gollapudi, 2005). It exerts cytotoxic effects on some cells,
but many are resistant to it. It has been known for some time
that AdE1A can sensitize otherwise resistant cells to TNFa-
induced apoptosis (Chen et al., 1987; Duerksen-Hughes et
al., 1989). In mouse fibroblasts, for example, the domains of
AdE1A responsible for inducing susceptibility to TNFa
involve N-terminal and/or CR2 regions which are the
binding sites for CBP/p300 and Rb (Shisler et al., 1996;
Cook et al., 2002). It has been suggested that CBP/p300
functions with NFnB to protect against TNFa cytotoxicity
(Vanden Berghe et al., 1999). AdE1A represses the TNFa-
induced NFnB activation response through interaction with
both CBP/p300 and Rb (Shao et al., 1999) or Rb alone
(Cook et al., 2002). It has been shown that TNFa-induced
apoptosis is a p53-dependent cellular response (Jeoung et
al., 1995). Indeed, restoration of wild-type p53 function in
p53 mutant cells increases their susceptibility to the
cytotoxic action of TNFa (Ameyar-Zazoua et al., 2002).
However, TNFa-induced apoptosis can also occur inde-pendently of p53 in human and mouse cells (Yoshida et al.,
1996; Cook et al., 1999).
Although increasing lines of evidence suggest that the
N-terminal and CR2 domains in AdE1A are essential for
interaction with CBP/p300, Rb, and the regulatory
components of the 26S proteasome and subsequent
inhibition of p53 degradation, the requirement for expres-
sion of p53 and binding to these proteins in AdE1A
sensitization to TNFa-induced apoptosis is still poorly
understood. We set out, in the present study, to investigate
the relationship between these two activities in TNFa-
induced apoptosis in human cells. The results presented
here demonstrate that expression of p53 enhances TNFa-
induced apoptosis and that AdE1A sensitizes otherwise
resistant cells to TNFa toxicity by stabilizing p53 through
the N-terminal and CR2 regions.Results
Both the N-terminal and CR2 regions of AdE1A are
required to sensitize A549 cells to TNFa-induced apoptosis
Experiments in mouse fibroblasts have shown that
mutant viruses with deletions in the N-terminal and CR2
regions of AdE1A were unable to induce sensitization to
TNFa-induced apoptosis (Shisler et al., 1996). Another
study reported that a deletion of CR2 alone was sufficient to
abrogate AdE1A sensitization in the same cells (Cook et al.,
2002). To determine the domains of AdE1A responsible for
the sensitization of human tumor cells to TNFa cytotoxicity,
we tested a number of AdE1A mutants.
Firstly, the AdE1A sensitization to the cytotoxicity of
TNFa was examined in non-small cell human lung
carcinoma cells (A549). Ad5 dl520 virus, which expresses
12S AdE1A but does not express 13S AdE1A, E1B 19K,
E1B 55K, and E3 proteins, was used for infection studies
since E1B and E3 genes possess anti-apoptotic activities
(Gooding et al., 1988; Wold, 1993; Burgert et al., 2002).
A549 cells were infected with Ad5 dl520 virus for 24 h then
treated with TNFa. The results show that approximately
29% of cells infected with Ad5 dl520 in the presence of
TNFa were apoptotic at 24 h, while less than 5% of cell
death was observed in samples treated with TNFa or the
virus alone (Fig. 1). These results demonstrate that A549
cells were initially resistant to the cytotoxicity of TNFa and
became sensitized by the expression of AdE1A. The
synergistic induction of apoptosis in A549 cells provided
a good model for the further studies on AdE1A sensitization
to TNFa.
Next, a panel of Ad5 mutant viruses derived from Ad5
dl520 with various deletions in AdE1A was used to infect
A549 cells. dl1101 and dl0106 had a deletion of amino
acids 4–25 at the N-terminus of AdE1A, and the latter had
additional deletions in the region between CR1 and CR2;
dl1108 had a deletion in the CR2 region, while dl0108 had a
Fig. 1. AdE1A sensitizes adenovirus-infected A549 cells to TNFa-induced
apoptosis. A549 cells were infected with adenovirus Ad5dl520 (50 pfu/
cell). 24 h post-infection, the cells were treated with or without TNFa (20
ng/ml) for a further 24 h, followed by fixation with ethanol and staining
with propidium iodide. The percentage of cytotoxicity was determined by
measuring DNA content of the sub-G1 population in stained cells using
FACS analysis. Uninfected cells were regarded as ‘‘mock’’.
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2A). After 24 h infection, cells were treated with TNFa for a
further 24 h prior to being photographed under phase-
contrast microscopy. It appeared that, like dl520, the
mutants dl1101, dl0106, and dl1108 enhanced cell sensi-
tivity to TNFa, but the double mutant dl0108 did not (Fig.
2B). Fig. 2C shows that the percentage of TNFa-induced
apoptosis produced by dl0107 and dl0108 was much less
(<10%) than that by the mutants dl520, dl1101, dl0106,
dl1107, or dl1108 (26–36%). The differences between
dl0107 or dl0108 and other mutants are statistically
significant (#P < 0.01). These findings are supported by
cell proliferation studies determined by alamarBlue assays.
Unlike dl520, dl1101, dl0106, dl1107, and dl1108, the
double mutant dl0107 or dl0108 did not induce significant
growth inhibition (Fig. 2D). These results demonstrate that
AdE1A sensitization is largely dependent on the amino
acid sequences in the N-terminal region and CR2 of
AdE1A since the viruses with deletions in these sites
(dl0107 and dl0108) failed to sensitize cells to TNFa-
induced apoptosis. Deletion of either the N-terminal region
(dl1101) or CR2 (dl1107 and dl1108) alone did not
abrogate AdE1A sensitization.
Adenovirus expressing 12S AdE1A only can replicate
under certain conditions during viral infection (Winberg and
Shenk, 1984). AdE1A mutants deleted in the N-terminal and
CR2 regions have been shown to prevent S-phase induction
and viral replication in tumor cells (Howe and Bayley, 1992;
Shisler et al., 1996; Somasundaram and El-Deiry, 1997;
Sauthoff et al., 2004). To test if the sensitization induced by
adenoviruses is a direct result of expression of AdE1Aproteins or a general response to viral replication, the levels
of AdE1A, along with the structural proteins hexon and
penton, were examined in A549 cells infected by various
viruses for 48 h. AdE1A was expressed at similar levels in
the cells infected by all the mutants. Viral structural proteins
were also expressed in all of the infected samples although
the levels in the cells infected with double mutant dl0107 or
dl0108 were slightly reduced (Fig. 2E). This result indicates
that expression of AdE1A with deletions in the N-terminus
and CR2 region may restrict the rate of viral replication,
which might, in turn, further inhibit the capacity of the
mutant viruses in the sensitization of TNFa cytotoxicity as
suggested by others (Sauthoff et al., 2004).
The ability of AdE1A to sensitize cells to TNFa-induced
apoptosis correlates with its ability to stabilize p53
Although it is well established that AdE1A can sensitize
cells to TNFa cytotoxicity and stabilize the p53 protein, the
relationship between these two activities in TNFa-treated
cells is not known. For this reason, we examined the regions
involved in both AdE1A sensitization and p53 stabilization
in human cells treated with TNFa. Since the mutant viruses
used in this study would produce other adenoviral proteins
such as E4Orf6 that might contribute to the effect of AdE1A
(Debbas and White, 1993; Moore et al., 1996), transient
transfection was used to express AdE1A in A549 cells.
Our results show that wild-type 12S AdE1A dramatically
enhanced TNFa-induced apoptosis (#P < 0.01), although
it did not induce marked cell death at 24 h on its own
(Fig. 3A). Similar to the results from viral infection,
expression of AdE1A from a double mutant containing
deletions in the N-terminal and CR2 regions (dl0108)
failed to sensitize cells to TNFa cytotoxicity. This result
confirms that expression of AdE1A protein alone directly
induces the sensitization to TNFa-induced cytotoxicity,
and actual viral replication plays only a minor role in the
process.
Accordingly, p53 levels in the transfected cells were
elevated by wt AdE1A but not by dl0108, while AdE1A
proteins were expressed at comparable levels (Fig. 3B).
Interestingly, the increase in p53 levels by AdE1A was not
accompanied by an increase of apoptosis in the absence of
TNFa. The enhancement of apoptosis by AdE1A was
observed only in cells treated with TNFa. The observation
that deletion of the N-terminal and CR2 regions abrogated
both AdE1A sensitization and stabilization of p53 in TNFa-
treated A549 cells clearly demonstrates that the accumu-
lation of p53 by AdE1A correlates closely to AdE1A
sensitization to TNFa cytotoxicity.
Induction of p53 overcomes cellular resistance to TNFa
toxicity
The results shown above suggest that the accumulation
of p53 might be critical in the regulation of the cellular
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Fig. 3. AdE1A sensitization in TNFa-induced apoptosis correlates to its
ability to stabilize p53 protein in transient transfected A549 cells. A549
cells were transfected with 4 Ag of pcDNA3-wtAdE1A plasmid which
expresses wild-type 12S, or with 4 Ag of pcDNA3-dl0108 plasmid with
deletions in N-terminal and CR2 regions of AdE1A. After 24 h, cells were
treated with 20 ng/ml of TNFa for a further 24 h. The cells were then
harvested and subjected to apoptosis analysis by FACS assays (A). Empty
vector pcDNA3 was used as control plasmid. Data were mean values of
duplicates from two independent experiments. #P < 0.01 when compared
with cells treated with TNFa alone. Expression of p53 and AdE1A proteins
were detected by Western blot analysis (B).
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further by transfection of pcDNA-p53 plasmid into H1299
cells that do not express endogenous p53 protein. H1299
cells were found to be resistant to TNFa cytotoxicity but
became sensitized following exogenous expression of p53
(Fig. 4A, #P < 0.01), indicating that p53 can overcome
cellular resistance to TNFa toxicity. Expression of p53 itself
did not induce apoptosis. In addition, we examined whether
increased expression of p53 would enhance TNFa cytotox-
icity in p53-expressing cells. A549 cells were initially
resistant to TNFa toxicity. Over-expression of p53, shown
as elevated p53 levels in cells transfected with pcDNA-p53,
did not increase apoptosis in the absence of TNFa. In the
presence of TNFa, however, a significant increase in the
percentage of apoptotic cells was seen in the cells where p53Fig. 2. AdE1A sensitizes TNFa-induced cell killing through its N-terminal and CR
mutant adenoviruses derived from Ad5dl520. The regions of deletions in the AdE
viruses (50 pfu/cell) for 24 h. After infection, the cells were treated with TNFa fo
ScionImage software (B). The infected cells were stained with acridine orange f
microscope (C). A549 cells were cultured in 96-well plates and infected with Ad5
(20 ng/ml) for a further 24 h and stained with alamarBlue dye at 37 -C for 4 h fo
triplicates (D) from two independent experiments. #P < 0.01 when compared
expression of AdE1A and viral structural proteins after infection for 48 h are prewas over-expressed (Fig. 4B, #P < 0.01). In contrast to the
observation by others (Kim et al., 2002), we found that
TNFa did not increase p53 level. The results suggest that
p53 protein could serve as a cause, but not a marker, of
enhanced cellular susceptibility to TNFa-induced apoptosis,
although induction of p53 itself need not be sufficient to
trigger apoptosis.
Expression of p53 enhances AdE1A sensitization to
TNFa-induced apoptosis
Subsequently, we examined whether expression of p53
can enhance AdE1A sensitization to TNFa-induced apop-
tosis. In p53-positive A549 cells, AdE1A stabilized p53 in
cells treated with or without TNFa, but apoptosis was
observed only in the presence of both AdE1A and TNFa. In
addition, additive accumulation of p53 by co-expression of
AdE1A and p53 did not increase apoptosis in the absence of
TNFa (Fig. 5A). However, an increase in the percentage of
apoptosis by co-expression of p53 and AdE1A was
observed in cells treated with TNFa (57%), when compared
to the samples treated with only AdE1A and TNFa (39%).
This indicates that over-expression of p53 was responsible
for the additional 18% increase in apoptosis observed in the
AdE1A sensitization (#P < 0.01). Moreover, with no
endogenous p53, H1299 cells were resistant to TNFa and
AdE1A sensitization (Fig. 5B). In the absence of TNFa,
expression of exogenous p53 and AdE1A did not signifi-
cantly increase apoptosis when compared with cells
expressing AdE1A alone (*P > 0.05). However, expression
of p53 protein in H1299 cells significantly enhanced
AdE1A sensitization to TNFa cytotoxicity (#P < 0.01).
The expression of p53 and AdE1A proteins was detected by
Western blot analysis. Based on the observation that
expression of p53 protein increased cell susceptibility to
TNFa toxicity and enhanced AdE1A sensitization, we
conclude that the accumulation of p53 protein is, at least
partly, responsible for AdE1A sensitization to TNFa-
induced apoptosis.
The proteasome inhibitor lactacystin promotes
TNFa-induced apoptosis regardless of expression of p53
and AdE1A
Our data suggested that AdE1A-induced sensitization
to TNFa cytotoxicity is related to the ability of AdE1A
to inhibit the activity of the 26S proteasome and the2 regions in adenovirus infected A549 cells. A549 cells were infected with
1A gene are shown in panel A. A549 cells were infected with Ad5 mutant
r 24 h prior to being photographed under phase-contrast microscopy using
luorescent dye. The percentage of apoptotic cells were counted under the
mutant viruses (50 pfu/cell) for 24 h. The cells were then treated with TNFa
r color development (D). The results were mean values of duplicates (C) or
to the samples treated with other mutant viruses. Western blots showing
sented in panel E.
Fig. 4. Induction of p53 protein increases cell susceptibility to TNFa-induced apoptosis and AdE1A sensitization. (A) H1299 cells were transfected with 0.5 Ag
of pcDNA3-p53 for 24 h, followed by treatment with 20 ng/ml of TNFa for a further 24 h. (B) A549 cells were transfected with 2 Ag of pcDNA3-p53 for 24 h,
followed by treatment with 20 ng/ml of TNFa for a further 24 h. The cells were then harvested and subjected to apoptosis analysis by FACS assays. Empty
vector pcDNA3 was used as control plasmid. Data were mean values of duplicates from two independent experiments. #P < 0.01 when compared with cells
treated with TNFa alone. Expression of p53 and AdE1A proteins were detected by Western blot analysis.
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effect of the proteasome inhibitor lactacystin on TNFa-
treated cells. Incubation with lactacystin causes accumu-Fig. 5. Expression of exogenous p53 proteins renders H1299 cells susceptible to T
transfected with 2 Ag of pcDNA3-p53 and 4 Ag of pcDNA3-12S AdE1A for 24 h, fo
compared with cells treated with AdE1A and TNFa. (B) H1299 cells were co-transfe
followed by treatmentwith 20 ng/ml of TNFa for a further 24 h. The cells were then h
values of duplicates from two independent experiments. #P < 0.01 when compared w
treated with AdE1A alone. Empty vector pcDNA3 was used as control plasmid. Exlation of polyubiquitinated proteins, including p53, in
apoptotic cells (Lopes et al., 1997). p53-positive (A549)
and p53-negative (H1299) cells were treated with lacta-NFa-induced apoptosis and AdE1A sensitization. (A) A549 cells were co-
llowed by treatment with 20 ng/ml of TNFa for a further 24 h. #P < 0.01 when
cted with 0.5 Ag of pcDNA3-p53 and 1 Ag of pcDNA3-12S AdE1A for 24 h,
arvested and subjected to apoptosis analysis by FACS assays. Data weremean
ith cells treated with AdE1A and TNFa. *P > 0.05 when compared with cells
pression of p53 and AdE1A proteins were detected by Western blot analysis.
Fig. 7. Lactacystin enhances TNFa-induced apoptosis and inhibits cell
X. Zhang et al. / Virology 340 (2005) 285–295 291cystin, in the absence or the presence of TNFa. The results
show that lactacystin enhanced TNFa-induced apoptosis in
both p53-negative and -positive cells (Fig. 6). This
indicates that TNFa could induce apoptosis through p53-
dependent and -independent pathways and that the
accumulation of other cellular proteins as a result of
proteasomal inhibition could also sensitize cells to TNFa
toxicity.
We have previously shown that a major mechanism
underlying p53 stabilization by AdE1A is the inhibition of
proteasome activity through the interaction of AdE1A with
the 19S regulatory components of the 26S proteasome
(Turnell et al., 2000; Zhang et al., 2004). In the present
study, we have compared the effects of accumulation of
p53 protein induced by AdE1A and lactacystin on the
cellular response to TNFa toxicity. A549 cells were
transfected with pcDNA3-12SAdE1A plasmid then treated
with lactacystin and TNFa (Fig. 7A). In the absence of
AdE1A, an additive effect was observed in cells treated
with both TNFa and lactacystin. While TNFa-induced
apoptosis was enhanced by the expression of AdE1A,
addition of lactacystin further increased the AdE1A
sensitization.
The effect of lactacystin on cell proliferation was also
evaluated (Fig. 7B). A549 cells were infected with Ad5
dl520 virus and then treated with lactacystin, in the absence
or the presence of TNFa. The data show that lactacystin
increased the inhibition of cell growth induced by AdE1A
and TNFa. Collectively, these data demonstrate an additiveFig. 6. The proteasome inhibitor lactacystin promotes TNFa-induced
apoptosis in tumor cells independent of p53 status. p53-negative H1299
cells (A) and p53-positive A549 (B) cells were treated for 24 h with the
proteasome inhibitor lactacystin (0.1, 1, or 10 AM), in the absence or the
presence of TNFa at concentration of 1 or 10 ng/ml. Cells were subjected to
apoptosis analysis by trypan blue exclusion assay. Data were mean values
of duplicates from two independent experiments.
growth in the absence or the presence of AdE1A. (A) A549 cells were
transfected with pcDNA3-12SAdE1A plasmid for 24 h, prior to further 24 h
incubation with lactacystin (10 AM), in the absence or the presence of 20
ng/ml of TNFa. Cells were subjected to apoptosis analysis by FACS assays.
Expression of p53 and AdE1A proteins were detected by Western blot
analysis. (B) A549 cells were cultured in 96-well plates and infected with
Ad5dl520 (50 pfu/cell) for 24 h. Cells were then treated with lactacystin (10
AM), in the absence or the presence of TNFa (20 ng/ml) for 24 h, prior to
cell proliferation analysis by alamarBlue assays. Data were mean values of
duplicates or triplicates from two independent experiments.effect of lactacystin on AdE1A sensitization in TNFa-
induced apoptosis and growth arrest.Discussion
We have previously shown that AdE1A’s interaction with
the regulatory complex of the 26S proteasome in vivo
requires the N-terminal region and CR2 (Turnell et al.,
2000; Zhang et al., 2004). In vitro mutational analysis has
revealed that AdE1A interacts with the S4 and S8 ATPase
subunits through its N-terminal region and binds to the S2
non-ATPase subunit through CR2 region. Deleting both N-
terminal and CR2 regions is needed for abrogation of
AdE1A’s interaction with the 26S proteasome in vivo. These
interactions result in an inhibition of 26S proteasomal
X. Zhang et al. / Virology 340 (2005) 285–295292activity, which causes the accumulation of p53 protein
(Zhang et al., 2004).
In the present study, we have investigated the biological
consequences of this interaction and established a correla-
tion between AdE1A-induced sensitization to TNFa-
induced apoptosis and stabilization of p53 in TNFa-treated
human A549 cells. Stabilization of p53 and sensitization to
TNFa-induced apoptosis required the N-terminal and CR2
regions of AdE1A that are also the binding sites for the 26S
proteasome (Figs. 2 and 3). This suggests that the
accumulation of p53 protein through inhibition of the 26S
proteasome might serve as a novel mechanism for AdE1A
in governing cell susceptibility to TNFa-induced apoptosis.
In p53-negative human H1299 cells, TNFa did not
induce apoptosis and AdE1A failed to enhance TNFa
cytotoxicity. However, expression of exogenous p53 over-
came the cellular resistance to TNFa toxicity (Fig. 4). These
results suggest that p53 plays a critical role in the TNFa
signaling pathway and that high levels of p53 are sufficient
for triggering TNFa-induced apoptosis. This is consistent
with other reports that infection of TNFa-resistant MCF7
cells with Adwtp53 restores cell sensitivity to TNFa toxicity
(Ameyar et al., 1999; Shatrov et al., 2000). We also
observed that over-expression of p53 additively enhanced
AdE1A sensitization to TNFa-induced apoptosis in the
otherwise resistant A549 cells, which endogenously express
wild-type p53 protein (Fig. 5). Given the finding that
induction of p53 overcame TNFa resistance and that
AdE1A sensitization to TNFa-induced apoptosis was
observed only when p53 was induced or stabilized, we
conclude that accumulation of p53 protein in response to
AdE1A is a key component of the mechanism by which
AdE1A sensitizes human cells to TNFa.
Our observation that reintroduction of p53 protein in
p53-negative cells restored cell susceptibility to TNFa
toxicity suggests that p53 can function as a key regulator,
governing the cellular response to TNFa. However, it does
not exclude the possibility that other cellular proteins are
involved. In the present study, the requirement for p53 in the
regulation of TNFa resistance was further evaluated using
the proteasome inhibitor lactacystin. This drug inhibits the
activity of the 20S proteasome complex and prevents the
degradation of numerous regulatory proteins, including p53,
resulting in an overload of conflicting signals in cancer cells
(Fenteany and Schreiber, 1998). Many of these signals
inhibit cell growth, eventually inducing apoptosis. Our data
show that lactacystin induced apoptosis in cells independent
of p53 status (Fig. 6), suggesting that the cell death can be
induced as a result of increased intracellular concentrations
of other regulatory proteins that are normally degraded by
the 26S proteasome. Not surprisingly, while expression of
p53 can overcome TNFa resistance and enhance TNFa-
induced apoptosis, it is not the sole factor regulating the
complex phenomenon of TNFa resistance and the sensiti-
zation to TNFa by AdE1A. For instance, it has been
reported that AdE1A can sensitize cells to TNFa cytotox-icity by down-regulating c-FLIP and preventing the
induction of c-FLIP by TNFa (Perez and White, 2003).
Interestingly, additive effects on the level of TNFa-induced
apoptosis were observed when A549 cells were treated with
AdE1A and lactacystin (Fig. 7), suggesting that AdE1A and
lactacystin could additively inhibit the 26S proteasomal
activity through targeting the regulatory complex and the
20S proteasome, respectively.
Previous studies have suggested that the molecular
mechanism underlying AdE1A sensitization to TNFa
cytotoxicity can be attributed to the interaction of AdE1A
with CBP/p300 and/or Rb, resulting in inhibition of NFnB
(Shisler et al., 1996; Shao et al., 1999; Cook et al., 2002).
Intriguingly, both CBP/p300 and Rb have been shown to
regulate p53 expression levels. Although CBP/p300 func-
tions as a co-activator of p53-dependent transcription, it also
enhances p53 turnover by stabilizing its negative regulator,
the Mdm2 ubiquitin ligase (Somasundaram and El-Deiry,
1997; Kawai et al., 2001; Grossman et al., 2003). Thus,
AdE1A can stabilize p53 by sequestering CBP/p300
(Querido et al., 1997). The inactivation of Rb by AdE1A
can also result in increased levels of p14ARF or p19ARF,
which then binds to and inactivates Mdm2, leading to a
stabilization of p53 (Bates et al., 1998; Sherr and
McCormick, 2002; Rocha et al., 2005). An indirect role
for Rb in the regulation of p53 function has also been
recently described. ASPP2 (53BP2L), a p53-binding protein
that promotes apoptosis, has been shown to be an E2F target
gene, indicating a role for Rb/E2F in regulating p53-
dependent apoptosis (Chen et al., 2005). Therefore, AdE1A
binding to Rb could free E2F to activate transcription of
ASPP2, ultimately stimulating p53-dependent apoptosis.
Further studies are needed to elucidate the role of Rb/E2F
pathway in the regulation of p53 stability and TNFa-
induced apoptosis.
Taking the existing literature and the results of the
present study into account, the evidence suggests that
targeting the 26S proteasome, CBP/p300, and Rb all
probably contribute to the sensitization of cells to TNFa-
induced apoptosis by AdE1A (Table 1). It seems possible
that the particular role attributable to each of these AdE1A
binding proteins could very likely depend on the cellular
context. The precise contribution of the interactions with
CBP/p300, Rb, and the 26S proteasome to the regulation of
p53 stability and AdE1A sensitization in TNFa-induced
apoptosis will be investigated in the future when AdE1A
mutants with differential binding capacities for these
proteins become available.
Taken together, the results from the present study
demonstrate that inhibition of proteasomal degradation and
subsequent accumulation of p53 is a novel mechanism by
which AdE1A sensitizes human cells to TNFa-induced
apoptosis. These observations also reveal that p53 plays a
key role in the regulation of TNFa-induced apoptosis.
AdE1A has already been utilized as a valuable tool in the
studies of molecular mechanisms of TNFa signaling path-
Table 1
Properties of adenoviruses expressing mutant AdE1A








Ad5dl520 125 wt + + + + +
Ad5dl1101 4–25  + + + +
Ad5dl1106 96–105 + + + + +
Ad5dl1107 111–123 +  + + +
Ad5dl1108 124–127 +  + + +
Ad5dl0106 4–25, 96–105  + + + +
Ad5dl0107 4–25, 111–123     
Ad5dl0108 4–25, 124–127     
Comparison of AdE1A’s interaction with CBP/p300, Rb, and 26S proteasome with its ability to stabilize p53 and to sensitize TNFa-induced apoptosis is listed
in this table. The findings for AdE1A’s binding capacity for CBP/p300, Rb, and the 26S proteasome were documented previously.
X. Zhang et al. / Virology 340 (2005) 285–295 293way (Sang et al., 2002) and our studies demonstrate that
AdE1A continues to be useful in unraveling the regulation
of this complex response. Recent progress has been made
towards the use of AdE1A-expressing adenovirus vectors in
cancer therapy (Dobbelstein, 2004). Our findings may be
useful in the development of new therapeutic strategies
involving AdE1A in adenoviral vectors delivering TNFa
and p53 genes for the treatment of human cancers.Materials and methods
Cell lines and reagents
A549 is a non-small cell human lung carcinoma cell line
expressing wild-type p53 and has been used for adenoviral
infection experiments. H1299 cells are derived from a p53-
null, non-small cell human lung carcinoma. Cells were
grown in HEPES-buffered DME supplemented with 8%
FCS and 2 mM glutamine. Human recombinant TNFa and
proteasome inhibitor lactacystin were purchased from R &
D Systems and Calbiochem, respectively.
Plasmids and transient transfection
A human pcDNA-p53 plasmid was kindly provided by
Prof. David Lane (University of Dundee). Constructs
containing Ad5 AdE1A mutants were described previously
(Zhang et al., 2004). For transient transfection experiments,
cells at 60–70% confluency were transfected with plasmids
using LipofectAMINE 2000 reagent (Invitrogen). After 24
h, cells were harvested or given further treatment. The total
amount of DNA used in each dish was kept constant using
the corresponding empty vector, pcDNA3, which was also
used in the control samples.
Viruses and viral infection
The adenovirus Ad5 dl520 used in this study is in the
Ad5 dl309 background, which lacks the E3 domain
encoding genes for E3 14.7K, 14.5K and 10.4K, but retains
the wild-type AdE1A region (Jones and Shenk, 1979). TheAd5 dl520 mutants were created to express Ad5 wt or
mutant 12SE1A, but not 13SE1A, E3, E1B 19K and E1B
55K proteins (Shepherd et al., 1993; Mymryk, 1998). The
positions of AdE1A mutations in the Ad5 dl520 mutants are
illustrated in Fig. 2A. For viral infection, sub-confluent
A549 cells were infected with 12S wt (dl520) or mutant
viruses in serum-free medium at 50 plaque forming units
(pfu)/cell for 2 h at 37 -C, with intermittent rocking.
Infected cells were then washed once and incubated in fresh
complete medium for 24 h prior to further treatment with
TNFa and/or lactacystin for detection of apoptosis and cell
proliferation.
Antibodies and Western blotting
Cells were harvested, after washing in ice-cold saline, by
scraping and aspiration. For Western blotting studies, they
were lysed in 9 M urea, 50 mM Tris–HCl (pH 7.3), and
0.15 M h-mercaptoethanol, and proteins were fractionated
by SDS-PAGE in the presence 0.1 M Tris, 0.1 M Bicine,
and 0.1% of SDS. After electrophoretic transfer to nitro-
cellulose membranes, antigens were detected using appro-
priate antibodies. Ad5AdE1A was detected with the mouse
monoclonals M58 (Pharmingen) and M73, whereas p53
was detected with the monoclonal antibody DO1. h-actin
was detected with a mouse monoclonal antibody (clone ac-
74, Sigma). Ad5 structural proteins were detected with a
rabbit polyclonal antibody (R1/99) raised against inacti-
vated virus.
Apoptosis assays
Floating and adherent cells were pooled and apoptotic
cells were identified and counted by staining the cells with
acridine orange dye and examining for apoptotic character-
istics under fluorescent microscopy. Cells with condensed
and fragmented nuclei were counted as apoptotic. For
apoptosis analysis in the proteasome inhibitor experiment,
trypan blue exclusion assays were performed according to
the instruction by the manufacturer (Sigma). At least 200
cells were counted in each experiment. In addition,
fluorescence activated cell sorter (FACS) analysis was
X. Zhang et al. / Virology 340 (2005) 285–295294carried out to detect propidium iodide-labeled apoptotic
cells in a sub-G1 population, as described previously
(Zhang et al., 2004).
Cell proliferation analysis
AlamarBluei reduction assay (Serotec Inc.) has been
used for evaluation of cell proliferation. Cells were cultured
in 96-well plates and infected with Ad5 viruses for 24 h
before incubation with TNFa and/or lactacystin for a further
24 h. Then, alamarBlue dye was added to the medium and
the cells were incubated for 4 h at 37 -C for color
development: pink indicated growing viable cells while
the blue suggested cell death according to the manufac-
turer’s instruction. The relative cell growth rate was
determined by analyzing optimal density data acquired
from a multi-well plate fluorometer at an excitation wave-
length of 530 nm and emission wavelength of 590 nm. The
fluorescence of the samples was corrected by comparison
with background fluorescence as determined by the blank
sample on each plate using software Ascent.
Statistics
Student’s t test was used to compare data between
groups while ANOVA test was applied to compare the data
among different groups. P < 0.05 was considered to be
statistically significant. Mean T SD was used to indicate
the average and standard deviation values from at least two
independent experiments with duplicate or triplicate
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